Remove Gene Silencing Remove Hormones Remove Licensing Remove Regulation
article thumbnail

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

pharmaphorum

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport ‘, a designation designed to speed up NHS access to promising new medicines.